Sleeping Beauty immunotherapy program
AssetAlso called TCR-T
Uses non-viral gene transfer to engineer T cells expressing T-cell receptors that recognize tumor-specific neoantigens.
- Stage
- Stage not known
- Modality
- Cell therapy
- Target
- EGFR
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
0In the full profile
- Target and mechanism3
- Owner and partners2
- Evidence for its targets3
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.